OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 302,369 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 302,369 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the transaction, the director owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

OrthoPediatrics Stock Down 0.6%

Shares of KIDS stock traded down $0.12 on Thursday, hitting $21.56. The company’s stock had a trading volume of 492,212 shares, compared to its average volume of 174,613. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. OrthoPediatrics Corp. has a fifty-two week low of $14.42 and a fifty-two week high of $26.74. The firm’s fifty day moving average price is $21.94 and its 200-day moving average price is $18.99. The stock has a market capitalization of $562.93 million, a price-to-earnings ratio of -12.83 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The firm had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. Research analysts anticipate that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on KIDS shares. Needham & Company LLC upped their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. BTIG Research lifted their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Finally, TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, OrthoPediatrics has an average rating of “Moderate Buy” and a consensus target price of $26.44.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC lifted its holdings in shares of OrthoPediatrics by 48.0% during the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock worth $24,802,000 after buying an additional 452,840 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of OrthoPediatrics in the second quarter worth $24,347,000. Vanguard Group Inc. grew its stake in shares of OrthoPediatrics by 1.1% in the third quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock worth $17,813,000 after acquiring an additional 10,927 shares during the last quarter. Granahan Investment Management LLC increased its position in OrthoPediatrics by 35.1% during the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock worth $14,231,000 after acquiring an additional 232,760 shares during the period. Finally, Wasatch Advisors LP increased its position in OrthoPediatrics by 56.6% during the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock worth $9,865,000 after acquiring an additional 186,357 shares during the period. 69.05% of the stock is owned by institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.